Veristat, LLC /
Certara, Inc.
Certara agrees to sell medical writing unit to Veristat
Source for the buyer and target: Certara, Inc.
For the buyer and target.
“On April 21, 2026, Certara, Inc. (the “Company”), together with certain of its subsidiaries, entered into a Purchase Agreement (the “Purchase Agreement”) with Veristat, LLC and certain of its affiliates (collectively, “Veristat”), pursuant to which the Company agreed to sell its global medical writing and related regulatory services business (the “Business”) to Veristat.”
Published 22 Apr 2026
Open the sourceWhat happened
Certara has agreed to sell its global medical writing and regulatory services business to Veristat. Veristat agreed to pay $100 million in cash, plus up to $35 million in earn-out payments tied to the business's performance after closing. [01]
The sale is subject to customary closing conditions, and Certara expects the transaction to close during the second quarter of 2026. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Certara agrees to sell medical writing unit to Veristat
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Expected close
“The sale is subject to customary closing conditions, and Certara expects the transaction to close during the second quarter of 2026”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly